Sign In
Buy ASND
$243.91
-7.16 (-2.85%)
At Close: Jul 31, 2026
Ascendis Pharma Hit By FDA Delay As TransCon CNP Decision Slips To 2026
10:13am, Friday, 28'th Nov 2025
The U.S. Food & Drug Administration (FDA) on Tuesday extended review for Ascendis Pharma A/S‘ (NASDAQ: ASND) New Drug Application (NDA) for TransCon CNP (navepegritide) for children with achondropla
Ascendis Pharma A/S $ASND Shares Bought by American Century Companies Inc.
03:05am, Wednesday, 26'th Nov 2025
American Century Companies Inc. lifted its position in Ascendis Pharma A/S (NASDAQ: ASND) by 14.9% during the second quarter, according to its most recent 13F filing with the SEC. The institutional in
US FDA extends review of Ascendis Pharma's therapy for children with dwarfism
06:21pm, Tuesday, 25'th Nov 2025
The U.S. Food and Drug Administration on Tuesday extended its review of Ascendis Pharma's therapy for children with a rare genetic disorder that causes dwarfism, the company said.
Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia
06:15pm, Tuesday, 25'th Nov 2025
– Prescription Drug User Fee Act (PDUFA) goal date extended by three months to February 28, 2026 COPENHAGEN, Denmark, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today ann
Artisan Partners Limited Partnership Decreases Position in Ascendis Pharma A/S $ASND
03:56am, Wednesday, 19'th Nov 2025
Artisan Partners Limited Partnership trimmed its holdings in shares of Ascendis Pharma A/S (NASDAQ: ASND) by 6.3% during the undefined quarter, according to the company in its most recent filing with
Results of Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics
04:01pm, Monday, 17'th Nov 2025
COPENHAGEN, Denmark, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that pivotal Week 52 results from its randomized double-blind, placebo-controlled ApproaCH Tri
Ascendis Pharma A/S (ASND) Q3 2025 Earnings Call Transcript
09:01pm, Wednesday, 12'th Nov 2025
Ascendis Pharma A/S (ASND) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Chad Fugere Jan Mikkelsen - President, CEO, Member of Executive Board & Executive Director Scott Smi
Ascendis Pharma Reports Third Quarter 2025 Financial Results
04:01pm, Wednesday, 12'th Nov 2025
– Q3 2025 revenue of €143.1 million for YORVIPATH ® and €50.7 million for SKYTROFA ®
Ascendis Pharma Likely To Report Narrower Q3 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
07:14am, Wednesday, 12'th Nov 2025
Ascendis Pharma A/S (NASDAQ:ASND) will release earnings results for the third quarter, after the closing bell on Wednesday, Nov. 12.
Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?
12:25pm, Monday, 10'th Nov 2025
Alto Neuroscience, Autolus Therapeutics, Ascendis Pharma and Immuneering are gearing up to report Q3 results that could top expectations.
COPENHAGEN, Denmark, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that a new pooled analysis showed sustained and clinically meaningful improvements in renal fu
Ascendis Pharma A/S $ASND Shares Purchased by Hantz Financial Services Inc.
04:26am, Thursday, 06'th Nov 2025
Hantz Financial Services Inc. boosted its holdings in Ascendis Pharma A/S (NASDAQ: ASND) by 291.1% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commi
Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025
04:01pm, Wednesday, 05'th Nov 2025
COPENHAGEN, Denmark, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report third quarter 2025 financial results and provide a business update on Wedne
COPENHAGEN, Denmark, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its data showing sustained improvements in renal function, continued normalization of uri
Top Growth Stocks To Follow Now – October 28th
02:10am, Thursday, 30'th Oct 2025
Prologis, Teledyne Technologies, Ascendis Pharma A/S, Hamilton Lane, Acadia Realty Trust, Canopy Growth, and Hercules Capital are the seven Growth stocks to watch today, according to MarketBeat's stoc
